immunotherapy added to chemotherapy improves pathological complete response in early triple nega...
Published 4 years ago • 104 plays • Length 6:52Download video MP4
Download video MP3
Similar videos
-
8:05
keynote-522: immune therapy and chemotherapy in patients with early triple negative breast cancer
-
7:15
pathologic complete response rates improved with the neoadjuvant and adjuvant treatment of pembr...
-
1:45
association of pathologic complete response following neoadjuvant chemotherapy with longterm sur...
-
4:54
keynote-522 updates: pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast...
-
4:24
comment: pembro plus chemo in neoadjuvant and adjuvant treatment for early triple-negative breas...
-
5:31
addition of atezolizumab to chemotherapy after surgery does not improve survival for triple nega...
-
3:39
steps for patients who do not receive complete response after neoadjuvant therapy
-
4:20
keynote-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer
-
13:03
early tnbc - pembrolizumab chemotherapy: pathologic complete response in key subgroups
-
2:52
neoadjuvant and adjuvant therapy in triple negative breast cancer
-
6:46
combining atezolizumab to neoadjuvant chemotherapy does not improve pathologic complete response...
-
1:46
exploratory analysis of keynote-522: efs after neoadjuvant pembro chemo vs chemo for early tnbc
-
1:29
immunotherapy keytruda shows benefit in early triple-negative breast cancer
-
3:28
immunotherapy in early-stage tnbc - where do we stand?
-
3:49
keynote-522: neoadjuvant pembro chemo vs placebo chemo, followed by adjuvant pembro vs place...
-
2:55
systemic immune response to durvalumab concomitant with neoadjuvant chemotherapy in early stage tncb
-
4:22
immunotherapy in early triple-negative breast cancer: new data and future directions
-
4:49
adding atezolizumab to adjuvant chemotherapy for stage ii and iii triple-negative breast cancer ...
-
2:05
treatment advances in tnbc